Research and Markets (http://www.researchandmarkets.com/research/6b6f68/pipeline_insight) has announced the addition of the "Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market" report to their offering.
Drugs with new mechanisms, in particular Pfizer's oral JAK inhibitor CP-690,550 and Chugai/Roche's Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. Late-stage pipeline launches will be a major contributor to market growth from $7.4 billion in 2008 to $11.5 billion in 2018.
Scope
- In-depth analysis of Phase II and III disease modifying drug candidates in the rheumatoid arthritis pipeline
- Segmentation and analysis of the current rheumatoid arthritis pipeline by developmental phase, drug class and company
- Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
- Focus on innovative early-stage drug development with assessment of future treatment of rheumatoid arthritis
Highlights of this title
The shift from Western regions to countries in Eastern Europe and South America is now a prominent feature of modern rheumatoid arthritis clinical trials. This has led to variability in placebo and drug responses resulting in higher failure rates. This will continue to be a difficult hurdle for drug development in rheumatoid arthritis.